Fragment-based drug discovery of small molecule ligands for the human chemokine CCL28

SLAS Discov. 2023 Jun;28(4):163-169. doi: 10.1016/j.slasd.2023.02.004. Epub 2023 Feb 23.

Abstract

The mucosal chemokine CCL28 is a promising target for immunotherapy drug development due to its elevated expression level in epithelial cells and critical role in creating and maintaining an immunosuppressive tumor microenvironment. Using sulfotyrosine as a probe, NMR chemical shift mapping identified a potential receptor-binding hotspot on the human CCL28 surface. CCL28 was screened against 2,678 commercially available chemical fragments by 2D NMR, yielding thirteen verified hits. Computational docking predicted that two fragments could occupy adjoining subsites within the sulfotyrosine recognition cleft. Dual NMR titrations confirmed their ability to bind CCL28 simultaneously, thereby validating an initial fragment pair for linking and merging strategies to design high-potency CCL28 inhibitors.

Keywords: CCL28; Chemokine; Drug discovery; Fragment; NMR; Sulfotyrosine.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chemokines* / metabolism
  • Chemokines, CC* / metabolism
  • Drug Discovery
  • Epithelial Cells / metabolism
  • Humans
  • Ligands

Substances

  • Ligands
  • Chemokines
  • Chemokines, CC
  • CCL28 protein, human